September 2008
Medical Device Daily;9/17/2008, Vol. 12 Issue 199, p4
The article reports on the announcement by MannKind and Pfizer that MannKind will transition certain Exubera patients with a continuing need for inhaled insulin to MannKind's inhaled insulin product, Technosphere Insulin. Pfizer announced earlier that it would discontinue marketing Exubera Inhalation Powder because it did not meet customers needs or Pfizer's financial expectations. Pfizer started negotiations with MannKind to give these patients access to Technosphere Insulin.


Related Articles

  • Studies Show No Increased Risk of Cardiac Events in Diabetes Patients Treated with AFREZZA(r).  // Biomedical Market Newsletter;6/30/2011, p59 

    The article reports on the findings of the study conducted at MannKind Corp. in California in 2011 for the diabetes patients treated with AFREZZA(r). It offers information on the effects of the inhaled AFREZZA on heart rate and cardiac morphology. It also mentions that the MannKind's next...

  • MannKind Reveals Next-Generation Inhalation System.  // Drug Discovery & Development;Sep2009, Vol. 12 Issue 8, p34 

    The article reports on the move of MannKind Corp. to begin clinical development of a next-generation inhalation system for optimization of drug powder delivery based on the proprietary Technosphere technology platform.

  • Biotech - Big Pharma Collaborations: Modified And Terminated Agreements, May 29 - June 25, 2009.  // BioWorld Insight;6/29/2009, Vol. 17 Issue 26, p12 

    The article offers information on the modified and terminated agreements between biotechnology and pharmaceutical firms in May 29-June 25, 2009. The biotechnology firm Alder Biopharmaceuticals Inc. modified its agreement with the pharmaceutical firm Schering-Plough Corp. as it now includes...

  • Research & Markets: Thought Leader Insight & Analysis Report - Diabetes/Obesity Q4 2010.  // Biomedical Market Newsletter;4/30/2011, p937 

    The article focuses on the report entitled "Thought Leader Insight & Analysis Report - Diabetes/Obesity Q4 2010." It notes that thought leaders from North America and Europe were interviewed by MedPredict to identify the promising candidates in clinical developments. Moreover, questions raised...

  • United States : SANOFI enters licensing agreement with MANNKIND CORP for Afrezza.  // TendersInfo News;8/14/2014, p1 

    The article reports on the signing of a worldwide exclusive licensing agreement between healthcare leader Sanofi and biopharmaceutical company MannKind Corp. to develop and commercialize Afrezza Inhalation Powder, a rapid-acting inhaled insulin therapy for adults with type I and II diabetes....

  • Recent Advances in the Development of an Inhaled Insulin Product. Valente, A.X.C.N.; Langer, R.; Stone, H.A.; Edwards, D.A. // BioDrugs;2003, Vol. 17 Issue 1, p9 

    Inhaled insulin first entered clinical human testing in the mid 1990s. Since then, the commercial potential and technical challenges of an inhaled insulin product have grown increasingly clear, with several pharmaceutical partnerships now targeting treatment of diabetes mellitus through...

  • Is Exubera Another GlucoWatch?  // Diabetes Health;Apr2006, Vol. 15 Issue 4, p42 

    Relates the opinions of endocrinologists on the potential of Exubera, the noninjectible insulin from Pfizer Inc., to succeed in the U.S. market in 2006. Cost consideration; Possible effect of the drug's absorption issues; Comparison with the Food and Drug Administration approved GlucoWatch...

  • Financings Roundup.  // BioWorld Today;8/18/2010, Vol. 21 Issue 159, p6 

    The article reports on MannKind Corp.'s plan to enter into a share-lending agreement with Bank of America in connection with its proposed offering of up to eight million shares of its common stock.

  • Financings Roundup.  // BioWorld Today;8/20/2010, Vol. 21 Issue 161, p3 

    The article reports that Valencia, California-based MannKind Corp. has participated in a stock lending agreement with Bank of America, wherein MannKind will lend 9 million shares of its stock with the bank.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics